Peptide immunotherapy.
Synthetic peptides representing T-cell epitopes of allergens and autoantigens have been employed to induce antigen-specific tolerance in vivo in experimental models and the clinical setting. Delivery of peptides orally or by injection leads to reduced reactivity to antigen accompanied by the induction of T cells with a regulatory phenotype. Peptide therapy may provide a safe, effective, and economically viable approach for disease-modifying therapy in autoimmune and allergic diseases.
Larché
Mark
M
Department of Allergy and Clinical Immunology, Faculty of Medicine, Imperial College, South Kensington, London SW7 2AZ, UK. m.larche@imperial.ac.uk
D000485:Allergens / Q000276:immunology; D003888:Desensitization, Immunologic / Q000379:methods*; D006801:Humans; D006967:Hypersensitivity / Q000276:immunology / Q000628:therapy*; D010455:Peptides / Q000627:therapeutic use*
D000485:Allergens; D010455:Peptides